Could fewer shots keep myeloma in check? new trial aims to cut costs and clinic visits
NCT ID NCT07485647
First seen Mar 24, 2026 · Last updated May 26, 2026 · Updated 13 times
Summary
This study tests whether giving the drug daratumumab less often (every 8 weeks, then every 16 weeks) along with lenalidomide is as effective as the standard every-4-week schedule for maintaining control of multiple myeloma after a stem cell transplant. The goal is to reduce treatment costs and the number of clinic visits while still keeping the cancer from coming back. About 50 adults with newly diagnosed multiple myeloma who have responded well to transplant will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37203, United States
Contact
Contact
Conditions
Explore the condition pages connected to this study.